New norovirus vaccine will help prevent local business continuity issues

Whilst most of the focus on the effects of communicable diseases on business continuity is understandably on pandemic-creating influenza viruses, the local impacts of another virus gain less headlines, even though they can be severe.

The virus in question is the norovirus, the so called 'cruise ship virus' which can quickly sweep through a community, such as a business office, a school or a hospital. The threat of the virus is in its high infection rates and its ability to rapidly produce debilitating symptons, including diarrhea / diarrhoea and explosive vomiting. An infection in the work-place can often require a complete closure to enable disinfection to take place. Even if this is not required, the number of employees absent due to a norovirus outbreak can have a real impact on business continuity.

Now help is at hand, as scientists have used a new vaccine production technology to develop a vaccine for norovirus. The new vaccine is unique in its origin — it was ‘manufactured’ in a tobacco plant using an engineered plant virus.

This plant biotechnology opens the door to more efficient, inexpensive ways to bring vaccines quickly to the public, especially critical in times when viruses mutate into unpredictable new strains, said Charles Arntzen, Ph.D., who reported on the topic recently at the 238th National Meeting of the American Chemical Society (ACS).

"The recent outbreak of H1N1 influenza virus has once again reminded us of the ability of disease-causing agents to mutate into new and dangerous forms," Arntzen points out. "It will be at least six months until a vaccine for this new strain will be available, and it will take even longer to create large stock piles of vaccine. For a case like the H1N1 influenza virus, you want to be able to move very rapidly and introduce a commercial vaccine in the shortest possible time. We think we have a major advantage in using engineered plant viruses to scale-up vaccine manufacture within weeks instead of months."

Noroviruses are always mutating, making it a moving target for vaccine developers. Arntzen says this has presented an obstacle for big pharmaceutical companies who might have considered developing a vaccine. Production costs can skyrocket when a single disease may frequently require new vaccines that must be developed and tested for safety and effectiveness. As a result, vaccines do not exist for many diseases that sicken enormous numbers of people each year. Arntzen notes that plant biotechnology could create a cheaper, quicker vaccine manufacturing technique uniquely suited to combat mutating viruses like norovirus and the flu.

Norovirus temporarily disables its victims, giving them severe diarrhea or nausea for up to three days. While not as life-threatening as the flu, Arntzen says it is equally important.
Norovirus will continue to evolve new strains, so Arntzen's team designed a vaccine manufacturing process quick enough to keep up with it and other shape-shifting viruses.

"With plant-based vaccines, we can generate the first gram quantities of the drug and do clinical tests within eight to 10 weeks… We could easily scale that up for commercial use in a two to four month period," explains Arntzen.

Plant-based vaccine production also offers cost advantages. Building greenhouses is more cost effective than the sterilized facilities, expensive manufacturing technology and stainless steel tanks required for the insect or mammalian cell cultures used in most traditional vaccines.

"The other cost advantages relate to vaccine purification and formulation. Purification from plant extracts is simpler because there are no infectious agents to clean up. There are no viruses in plants which can infect humans, so you don't have to worry about viral removal," notes Arntzen.

The team re-engineered plant viruses to produce high levels of specially designed ‘virus-like’ nanoparticles in tobacco plants. At about 25 nanometers in diameter, the particles are about the same size as the norovirus, but they consist only of the outer surface protein — the portion of the virus recognized by the human immune system. The particles contain none of the infectious material of the original virus, but they stimulate a robust immune response to fight off an actual infection.

To battle each new strain of the norovirus and to keep full resistance to older strains, Arntzen says the vaccine could be administered as a booster every 12 to 18 months.

After successful experiments in mice, his team is developing a nasal delivery system for the virus-like particles. Arntzen expects to start clinical trials in late 2009 or early 2010.

•Date: 20th August 2009• Region: US/World •Type: Article •Topic: BC general
Rate this article or make a comment - click here